By Order dated May 5, 2005, the Supreme Court designated New Jersey state-court litigation involving the drug Accutane as a mass tort and assigned it to Atlantic County for centralized case management by Superior Court Judge Carol E. Higbee. Judge Higbee has reported that over the past several years an increased number of cases involving the generic version of Accutane – Isotretinoin – have been filed in Atlantic County. She has recommended that litigation against the manufacturers of Isotretinoin – Mylan Bertek Pharmaceuticals; Mylan Pharmaceuticals, Inc.; Mylan Inc.; Ranbaxy Inc.; Ranbaxy Pharmaceuticals Inc.; Ranbaxy Laboratories Inc.; Barr Pharmaceuticals LLC; Barr Laboratories, Inc.; Cardinal Health 409 Inc.; Genpharm; and Genpharm ULC) – be designated as part of the Accutane Litigation.
This Notice is to advise of the proposed amendment of the May 5, 2005 Order so as to designate the Isotretinoin (Generic Accutane) Litigation as part of the Accutane Litigation. Any comments on or objections to the proposed action must be submitted in writing, with relevant supporting documentation, to the Administrative Director of the Courts, P. O. Box 037, Trenton, NJ 08625-0037, by April 15, 2011. Comments also may be submitted by e-mail to Comments.Mailbox @judiciary.state.nj.us. Once this comment period has closed, the proposed designation of the Isotretinoin (Generic Accutane) Litigation as part of the Accutane Litigation will be submitted to the Supreme Court for its consideration and action.
Any questions concerning this proposed action may be directed to Taironda E. Phoenix, Esq., Staff Attorney, Civil Practice Division, Administrative Office of the Courts, Hughes Justice Complex, P.O. Box 981, Trenton, New Jersey 08625-0981; Telephone (609) 292-8471, e-mail address: taironda.phoenix@judiciary.state.nj.us.
Glenn A. Grant, J.A.D.
Acting Administrative Director of the Courts
Document Date: March 14, 2011
Publish Date: March 28, 2011